Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: A propensity score‐based weighting
Masaaki Kondo(Yokohama City University Medical Center), Katsuaki Tanaka(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Satoshi Kobayashi(Kanagawa Cancer Center), Tomohiro Ishii(Tokyo Metropolitan Children's Medical Center), Takahide Nakazawa(Kitasato University Hospital), Akito Nozaki(Yokohama City University Medical Center), Akitaka Shibuya, Hiroyuki Fukuda(Yokohama City University Medical Center), Kentaro Sakamaki(Yokohama City University), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Satoshi Morita(Kyoto University), Chiaki Okuse(St. Marianna University School of Medicine), Shinichi Ohkawa(National Cancer Center Hospital East), Shin Maeda(University of Tokyo Hospital), Michihiro Suzuki(Tamagawa University), Hisashi Hidaka(Kitasato University)
Cited by 20
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k